| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenues | $228.9M+22.0% | $187.6M+25.0% | $150.0M+25.5% | $119.6M+5.2% | $113.7M |
| Cost of revenue, excluding depreciation and amortization | $130.5M+28.8% | $101.3M+34.7% | $75.2M | — | — |
| Research and development, net | $9.5M-7.2% | $10.3M-39.8% | $17.1M-21.2% | $21.7M+36.1% | $15.9M |
| Clinical operations, net | $7.2M+10.2% | $6.5M+6.2% | $6.2M-6.6% | $6.6M-29.6% | $9.4M |
| Sales and marketing | $53.8M+6.5% | $50.5M-3.3% | $52.2M-28.3% | $72.8M-27.6% | $100.6M |
| General and administrative | $21.8M-3.6% | $22.6M+6.0% | $21.3M-41.3% | $36.3M+4.3% | $34.8M |
| Depreciation and amortization | $2.9M+234.7% | $859K-33.2% | $1.3M | — | — |
| Total costs and operating expenses | $225.7M+17.5% | $192.1M+10.9% | $173.3M+20.7% | $143.5M-10.7% | $160.7M |
| Income (loss) from operations | $3.2M+170.1% | -$4.5M+80.6% | -$23.2M+72.1% | -$83.2M+11.5% | -$93.9M |
| Financial income, net | -$5.2M+9.1% | -$5.7M-35.2% | -$4.2M-13.5% | -$3.7M+88.0% | -$31.2M |
| Income (loss) before income taxes | $8.4M+573.7% | $1.2M+106.5% | -$19.0M+76.1% | -$79.4M-26.7% | -$62.7M |
| Income tax expense | $574K+510.6% | $94K-56.9% | $218K-14.2% | $254K+440.4% | $47K |
| Net income (loss) | $7.8M+578.8% | $1.1M+106.0% | -$19.2M+75.9% | -$79.7M-27.0% | -$62.7M |
| Basic | $167.09B-1.1% | $168.91B+2.3% | $165.04B+32360768627551.0% | -$0.51+29.2% | -$0.72 |
| Diluted | $173.65B-1.6% | $176.50B+6.9% | $165.04B+32360768627551.0% | -$0.51+29.2% | -$0.72 |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.